Human DNA Vaccine Market - Global Industry Size, Share, Trends, Competition, Opportunity, and Forecast, 2018-2028 Segmented By Mode of Administration (Intramuscular, Subcutaneous, Intradermal, Others), By Application (Oncology, Tuberculosis, HIV, Human Papillomavirus, Others), By End User (Hospitals & Clinics, Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, Others), By Region and Competition
Global Human DNA Vaccine Market is anticipated to observe impressive growth during the forecast period, 2024-2028, owing to the growing prevalence of cancer and infectious diseases in humans. According to Global Cancer Observatory, in 2020, around 19,292,789 new cancer cases were reported worldwide. Breast Cancer, Lung Cancer, Colorectum Cancer, Prostate Cancer, and Stomach Cancer were the most prevalent types of cancer cases reported in 2020. Additionally, an increase in the number of antibiotic-resistant pathogens is further expected to drive the growth of the human DNA Vaccine Market.
The growing prevalence of different diseases has significantly increased the demand for different types of vaccines. Additionally, growing research & development activities being initiated by various governments and pharmaceutical & biotechnology companies across the globe are further expected to create lucrative opportunities for the growth of the human DNA vaccine market in the coming years. In 2021, the research & development expenditure in the pharmaceutical industry across the globe was around USD238 billion.
Rise in Prevalence of Different Diseases
Globally, cancer is the leading cause of death. According to World Health Organization, around 50,550,287 cases of cancer prevalence have been reported worldwide in the last five years. This is due to the physical carcinogens, such as ultraviolet and ionizing radiation; chemical carcinogens, such as asbestos, components of tobacco smoke, alcohol, aflatoxin (a food contaminant), and arsenic (a drinking water contaminant) and biological carcinogens, such as infections from certain viruses, bacteria, or parasites as well as unhealthy lifestyle. Cancer has become a global healthcare concern. The need to develop therapies for cancer is expected to support the growth of global human DNA vaccine market. Similarly, the increasing prevalence of diseases such as HIV, Human Papillomavirus, and Tuberculosis, which are deadly and require a potential treatment, is further expected to drive the growth of global human DNA vaccine market. As of 2021, globally, around 38.4 million people were living with HIV.
Increase in Number of Antibiotics Resistant Pathogens
Antibiotic resistance is one of the biggest threats to global health, food security, and development. The epidemiological models describe a direct relationship between antibiotic consumption and resistant pathogen. According to World Health Organization, 32 antibiotics were identified in clinical development, which addressed the top priority pathogens. Some multi and resistant bacteria called “superbugs” that cause infections are not treatable with existing antimicrobial medicines such as antibiotics. Also, certain bacteria have developed resistance to existing treatment options, thereby creating a need to develop novel therapeutic solutions which can address the issue of antibiotic resistance. This, in turn, is expected to fuel the growth of Global Human DNA Vaccine Market.
Growth in R&D for DNA Vaccine
Rapid advancements in research and development (R&D) practices and activities are propelling the growth of the market on account of the growing need to develop novel human vaccines for the treatment of different life-threatening diseases. According to Clinicaltrials.gov, 247 clinical trials are in different phases of development across the globe for Human DNA vaccines. This clearly indicates that a lot of R&D is being done across the globe for developing human DNA vaccines for the treatment of different diseases, thereby supporting the growth of the global human DNA vaccine market.
Recent Developments
ZyCoV-D is a DNA plasmid-based COVID-19 vaccine developed by Indian pharmaceutical company Cadila Healthcare, with support from the Biotechnology Industry Research Assistance Council in August 2021. This vaccine illustrated higher safety, efficacy, and immunogenicity. The vaccine is administered into the skin without an injection and has been found to be 67% protective against symptomatic COVID-19 in clinical trials. ZyCoV-D is a three-dose intradermal vaccine applied using The PharmaJet needle-free system, Tropis, which can significantly reduce any side effects and improve quality. Zydus Cadila has received approval for Emergency Use Authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D.
Market Segmentation
Global Human DNA Vaccine Market can be segmented based on the mode of administration, application, end user, and region. Based on the mode of administration, the market can be categorized into intramuscular, subcutaneous, intradermal, and others. Based on application, the market can be fragmented into oncology, tuberculosis, HIV, human papillomavirus, and others. Based on end users, the market can be grouped into hospitals & clinics, biotechnology & pharmaceutical companies, academic & research institutions, and others.
Company Profiles
BOEHRINGER INGELHEIM GmbH (Merial), ELI-LILLY (Novartis Animal Health), Gene One Life Science, GEOVAX LABS, INC, Inovio Pharmaceuticals (VGX Animal Health), Genexine, Inc., VIATRIS INC. (Rottapharm Biotech), Takara Holdings (Takara Bio), ZOETIS INC. (Fort Dodge Animal Health), Zydus Lifesciences Limited are some of the key players operating in the global Human DNA Vaccine market.
Report Scope:
In this report, Global Human DNA Vaccine Market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in Global Human DNA Vaccine market.
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:
Company Information
The growing prevalence of different diseases has significantly increased the demand for different types of vaccines. Additionally, growing research & development activities being initiated by various governments and pharmaceutical & biotechnology companies across the globe are further expected to create lucrative opportunities for the growth of the human DNA vaccine market in the coming years. In 2021, the research & development expenditure in the pharmaceutical industry across the globe was around USD238 billion.
Rise in Prevalence of Different Diseases
Globally, cancer is the leading cause of death. According to World Health Organization, around 50,550,287 cases of cancer prevalence have been reported worldwide in the last five years. This is due to the physical carcinogens, such as ultraviolet and ionizing radiation; chemical carcinogens, such as asbestos, components of tobacco smoke, alcohol, aflatoxin (a food contaminant), and arsenic (a drinking water contaminant) and biological carcinogens, such as infections from certain viruses, bacteria, or parasites as well as unhealthy lifestyle. Cancer has become a global healthcare concern. The need to develop therapies for cancer is expected to support the growth of global human DNA vaccine market. Similarly, the increasing prevalence of diseases such as HIV, Human Papillomavirus, and Tuberculosis, which are deadly and require a potential treatment, is further expected to drive the growth of global human DNA vaccine market. As of 2021, globally, around 38.4 million people were living with HIV.
Increase in Number of Antibiotics Resistant Pathogens
Antibiotic resistance is one of the biggest threats to global health, food security, and development. The epidemiological models describe a direct relationship between antibiotic consumption and resistant pathogen. According to World Health Organization, 32 antibiotics were identified in clinical development, which addressed the top priority pathogens. Some multi and resistant bacteria called “superbugs” that cause infections are not treatable with existing antimicrobial medicines such as antibiotics. Also, certain bacteria have developed resistance to existing treatment options, thereby creating a need to develop novel therapeutic solutions which can address the issue of antibiotic resistance. This, in turn, is expected to fuel the growth of Global Human DNA Vaccine Market.
Growth in R&D for DNA Vaccine
Rapid advancements in research and development (R&D) practices and activities are propelling the growth of the market on account of the growing need to develop novel human vaccines for the treatment of different life-threatening diseases. According to Clinicaltrials.gov, 247 clinical trials are in different phases of development across the globe for Human DNA vaccines. This clearly indicates that a lot of R&D is being done across the globe for developing human DNA vaccines for the treatment of different diseases, thereby supporting the growth of the global human DNA vaccine market.
Recent Developments
ZyCoV-D is a DNA plasmid-based COVID-19 vaccine developed by Indian pharmaceutical company Cadila Healthcare, with support from the Biotechnology Industry Research Assistance Council in August 2021. This vaccine illustrated higher safety, efficacy, and immunogenicity. The vaccine is administered into the skin without an injection and has been found to be 67% protective against symptomatic COVID-19 in clinical trials. ZyCoV-D is a three-dose intradermal vaccine applied using The PharmaJet needle-free system, Tropis, which can significantly reduce any side effects and improve quality. Zydus Cadila has received approval for Emergency Use Authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D.
Market Segmentation
Global Human DNA Vaccine Market can be segmented based on the mode of administration, application, end user, and region. Based on the mode of administration, the market can be categorized into intramuscular, subcutaneous, intradermal, and others. Based on application, the market can be fragmented into oncology, tuberculosis, HIV, human papillomavirus, and others. Based on end users, the market can be grouped into hospitals & clinics, biotechnology & pharmaceutical companies, academic & research institutions, and others.
Company Profiles
BOEHRINGER INGELHEIM GmbH (Merial), ELI-LILLY (Novartis Animal Health), Gene One Life Science, GEOVAX LABS, INC, Inovio Pharmaceuticals (VGX Animal Health), Genexine, Inc., VIATRIS INC. (Rottapharm Biotech), Takara Holdings (Takara Bio), ZOETIS INC. (Fort Dodge Animal Health), Zydus Lifesciences Limited are some of the key players operating in the global Human DNA Vaccine market.
Report Scope:
In this report, Global Human DNA Vaccine Market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:
- Human DNA Vaccine Market, By Mode of Administration:
- Intramuscular
- Subcutaneous
- Intradermal
- Others
- Human DNA Vaccine Market, By Application:
- Oncology
- Tuberculosis
- HIV
- Human Papillomavirus
- Others
- Human DNA Vaccine Market, By End User:
- Hospitals & Clinics
- Biotechnology & Pharmaceutical Companies
- Academic & Research Institutions
- Others
- Human DNA Vaccine Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- UAE
- Saudi Arabia
- South Africa
- Turkey
- Egypt
Company Profiles: Detailed analysis of the major companies present in Global Human DNA Vaccine market.
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL HUMAN DNA VACCINE MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Route of Administration (Intramuscular, Subcutaneous, Intradermal, Others include (Intravenous, etc.)
5.2.2. By Application (Oncology, Tuberculosis, HIV, Others include (Hepatitis, Influenza, etc.)
5.2.3. By End User (Hospitals & Clinics, Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, Others include (Ambulatory surgical centers, Nursing homes, etc.)
5.2.4. By Region (North America, Europe, Asia Pacific, South America, Middle-East and Africa)
5.2.5. By Company (2022)
5.3. Market Map
5.3.1. By Route of Administration
5.3.2. By Application
5.3.3. By End User
5.3.4. By Region
6. NORTH AMERICA HUMAN DNA VACCINE MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Route of Administration
6.2.2. By Application
6.2.3. By End User
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Human DNA Vaccine Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Route of Administration
6.3.1.2.2. By Application
6.3.1.2.3. By End User
6.3.2. Canada Human DNA Vaccine Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Route of Administration
6.3.2.2.2. By Application
6.3.2.2.3. By End User
6.3.3. Mexico Human DNA Vaccine Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Route of Administration
6.3.3.2.2. By Application
6.3.3.2.3. By End User
7. EUROPE HUMAN DNA VACCINE MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Route of Administration
7.2.2. By Application
7.2.3. By End User
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Human DNA Vaccine Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Route of Administration
7.3.1.2.2. By Application
7.3.1.2.3. By End User
7.3.2. France Human DNA Vaccine Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Route of Administration
7.3.2.2.2. By Application
7.3.2.2.3. By End User
7.3.3. United Kingdom Human DNA Vaccine Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Route of Administration
7.3.3.2.2. By Application
7.3.3.2.3. By End User
7.3.4. Italy Human DNA Vaccine Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1.1. By Route of Administration
7.3.4.2.1.2. By Application
7.3.4.2.1.3. By End User
7.3.5. Spain Human DNA Vaccine Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Route of Administration
7.3.5.2.2. By Application
7.3.5.2.3. By End User
8. ASIA-PACIFIC HUMAN DNA VACCINE MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Route of Administration
8.2.2. By Application
8.2.3. By End User
8.2.4. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Human DNA Vaccine Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Route of Administration
8.3.1.2.2. By Application
8.3.1.2.3. By End User
8.3.2. Japan Human DNA Vaccine Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Route of Administration
8.3.2.2.2. By Application
8.3.2.2.3. By End User
8.3.3. India Human DNA Vaccine Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Route of Administration
8.3.3.2.2. By Application
8.3.3.2.3. By End User
8.3.4. South Korea Human DNA Vaccine Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Route of Administration
8.3.4.2.2. By Application
8.3.4.2.3. By End User
8.3.5. Australia Human DNA Vaccine Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Route of Administration
8.3.5.2.2. By Application
8.3.5.2.3. By End User
9. SOUTH AMERICA HUMAN DNA VACCINE MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Route of Administration
9.2.2. By Application
9.2.3. By End User
9.2.4. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Human DNA Vaccine Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Route of Administration
9.3.1.2.2. By Application
9.3.1.2.3. By End User
9.3.2. Argentina Human DNA Vaccine Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Route of Administration
9.3.2.2.2. By Application
9.3.2.2.3. By End User
9.3.3. Colombia Human DNA Vaccine Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Route of Administration
9.3.3.2.2. By Application
9.3.3.2.3. By End User
10. MIDDLE EAST AND AFRICA HUMAN DNA VACCINE MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Route of Administration
10.2.2. By Application
10.2.3. By End User
10.2.4. By Country
10.3. MEA: Country Analysis
10.3.1. UAE Human DNA Vaccine Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Route of Administration
10.3.1.2.2. By Application
10.3.1.2.3. By End User
10.3.2. Saudi Arabia Human DNA Vaccine Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Route of Administration
10.3.2.2.2. By Application
10.3.2.2.3. By End User
10.3.3. South Africa Human DNA Vaccine Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Route of Administration
10.3.3.2.2. By Application
10.3.3.2.3. By End User
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
13. CLINICAL TRIAL ANALYSIS
13.1. Ongoing Clinical Trials
13.2. Completed Clinical Trials
13.3. Terminated Clinical Trials
13.4. Breakdown of Pipeline, By Development Phase
13.5. Breakdown of Pipeline, By Status
13.6. Breakdown of Pipeline, By Study Application
13.7. Breakdown of Pipeline, By Region
13.8. Clinical Trials Heat Map
14. COMPETITIVE LANDSCAPE
14.1. Business Overview
14.2. Product Offerings
14.3. Recent Developments
14.4. Financials (In Case of Listed Companies)
14.5. Key Personnel
14.5.1. BOEHRINGER INGELHEIM GmbH (Merial)
14.5.2. ELI-LILLY (Novartis Animal Health)
14.5.3. GeneOne Life Science
14.5.4. GEOVAX LABS, INC
14.5.5. Inovio Pharmaceuticals (VGX Animal Health)
14.5.6. Genexine, Inc.
14.5.7. VIATRIS INC. (Rottapharm Biotech)
14.5.8. Takara Holdings (Takara Bio)
14.5.9. ZOETIS INC. (Fort dodge Animal Health)
14.5.10. Zydus Cadila
15. STRATEGIC RECOMMENDATIONS
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL HUMAN DNA VACCINE MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Route of Administration (Intramuscular, Subcutaneous, Intradermal, Others include (Intravenous, etc.)
5.2.2. By Application (Oncology, Tuberculosis, HIV, Others include (Hepatitis, Influenza, etc.)
5.2.3. By End User (Hospitals & Clinics, Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, Others include (Ambulatory surgical centers, Nursing homes, etc.)
5.2.4. By Region (North America, Europe, Asia Pacific, South America, Middle-East and Africa)
5.2.5. By Company (2022)
5.3. Market Map
5.3.1. By Route of Administration
5.3.2. By Application
5.3.3. By End User
5.3.4. By Region
6. NORTH AMERICA HUMAN DNA VACCINE MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Route of Administration
6.2.2. By Application
6.2.3. By End User
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Human DNA Vaccine Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Route of Administration
6.3.1.2.2. By Application
6.3.1.2.3. By End User
6.3.2. Canada Human DNA Vaccine Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Route of Administration
6.3.2.2.2. By Application
6.3.2.2.3. By End User
6.3.3. Mexico Human DNA Vaccine Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Route of Administration
6.3.3.2.2. By Application
6.3.3.2.3. By End User
7. EUROPE HUMAN DNA VACCINE MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Route of Administration
7.2.2. By Application
7.2.3. By End User
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Human DNA Vaccine Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Route of Administration
7.3.1.2.2. By Application
7.3.1.2.3. By End User
7.3.2. France Human DNA Vaccine Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Route of Administration
7.3.2.2.2. By Application
7.3.2.2.3. By End User
7.3.3. United Kingdom Human DNA Vaccine Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Route of Administration
7.3.3.2.2. By Application
7.3.3.2.3. By End User
7.3.4. Italy Human DNA Vaccine Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1.1. By Route of Administration
7.3.4.2.1.2. By Application
7.3.4.2.1.3. By End User
7.3.5. Spain Human DNA Vaccine Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Route of Administration
7.3.5.2.2. By Application
7.3.5.2.3. By End User
8. ASIA-PACIFIC HUMAN DNA VACCINE MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Route of Administration
8.2.2. By Application
8.2.3. By End User
8.2.4. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Human DNA Vaccine Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Route of Administration
8.3.1.2.2. By Application
8.3.1.2.3. By End User
8.3.2. Japan Human DNA Vaccine Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Route of Administration
8.3.2.2.2. By Application
8.3.2.2.3. By End User
8.3.3. India Human DNA Vaccine Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Route of Administration
8.3.3.2.2. By Application
8.3.3.2.3. By End User
8.3.4. South Korea Human DNA Vaccine Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Route of Administration
8.3.4.2.2. By Application
8.3.4.2.3. By End User
8.3.5. Australia Human DNA Vaccine Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Route of Administration
8.3.5.2.2. By Application
8.3.5.2.3. By End User
9. SOUTH AMERICA HUMAN DNA VACCINE MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Route of Administration
9.2.2. By Application
9.2.3. By End User
9.2.4. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Human DNA Vaccine Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Route of Administration
9.3.1.2.2. By Application
9.3.1.2.3. By End User
9.3.2. Argentina Human DNA Vaccine Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Route of Administration
9.3.2.2.2. By Application
9.3.2.2.3. By End User
9.3.3. Colombia Human DNA Vaccine Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Route of Administration
9.3.3.2.2. By Application
9.3.3.2.3. By End User
10. MIDDLE EAST AND AFRICA HUMAN DNA VACCINE MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Route of Administration
10.2.2. By Application
10.2.3. By End User
10.2.4. By Country
10.3. MEA: Country Analysis
10.3.1. UAE Human DNA Vaccine Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Route of Administration
10.3.1.2.2. By Application
10.3.1.2.3. By End User
10.3.2. Saudi Arabia Human DNA Vaccine Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Route of Administration
10.3.2.2.2. By Application
10.3.2.2.3. By End User
10.3.3. South Africa Human DNA Vaccine Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Route of Administration
10.3.3.2.2. By Application
10.3.3.2.3. By End User
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
13. CLINICAL TRIAL ANALYSIS
13.1. Ongoing Clinical Trials
13.2. Completed Clinical Trials
13.3. Terminated Clinical Trials
13.4. Breakdown of Pipeline, By Development Phase
13.5. Breakdown of Pipeline, By Status
13.6. Breakdown of Pipeline, By Study Application
13.7. Breakdown of Pipeline, By Region
13.8. Clinical Trials Heat Map
14. COMPETITIVE LANDSCAPE
14.1. Business Overview
14.2. Product Offerings
14.3. Recent Developments
14.4. Financials (In Case of Listed Companies)
14.5. Key Personnel
14.5.1. BOEHRINGER INGELHEIM GmbH (Merial)
14.5.2. ELI-LILLY (Novartis Animal Health)
14.5.3. GeneOne Life Science
14.5.4. GEOVAX LABS, INC
14.5.5. Inovio Pharmaceuticals (VGX Animal Health)
14.5.6. Genexine, Inc.
14.5.7. VIATRIS INC. (Rottapharm Biotech)
14.5.8. Takara Holdings (Takara Bio)
14.5.9. ZOETIS INC. (Fort dodge Animal Health)
14.5.10. Zydus Cadila
15. STRATEGIC RECOMMENDATIONS
